Left ventricular diastolic dysfunction in diabetic patients: Pathophysiology and therapeutic implications

American Journal of Cardiovascular Drugs

Volumn 6, Issue 4, 2006, Pages 219-230

  Tsujino, Takeshi ^a   Kawasaki, Daizo ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ALDOSTERONE ANTAGONIST; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; BISOPROLOL; CANDESARTAN HEXETIL; CARVEDILOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; METFORMIN; METOPROLOL; NEBIVOLOL; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; VERAPAMIL; VOGLIBOSE;

CALCIUM TRANSPORT; CARDIOVASCULAR RISK; CARDIOVERSION; CELL STRUCTURE; CLINICAL TRIAL; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIALYSIS; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG CONTRAINDICATION; DYSLIPIDEMIA; DYSPNEA; EDEMA; ELECTROCARDIOGRAPHY; FATTY ACID METABOLISM; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HIGH ENERGY PHOSPHATE; HORMONAL REGULATION; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LONG TERM CARE; LUNG CONGESTION; MEDICAL ASSESSMENT; MICROANGIOPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM RESTRICTION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 33747871135     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606040-00002     Document Type: Review

References (142)

1. American Heart Association. 2002 heart and stroke statistical update. Dallas (TX): American Heart Association, 2003
2. Miller LW, Missov ED. Epidemiology of heart failure. Cardiol Clin 2001; 19 (4): 547-55
3. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 2001; 88 (5): 530-3
4. Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, Zipes DP, Libby P, editors. 6th ed. Heart disease: a textbook of cardiovascular medicine. Philadelphia (PA): Saunders, 2001: 503
5. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26 (7): 1565-74
6. Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003; 41 (9): 1510-8
7. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33 (7): 1948-55
8. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 1999; 20 (6): 447-55
9. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999; 138 (1 Pt 1): 87-94
10. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98 (21): 2282-9
11. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350 (19): 1953-9
12. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998; 19 (7): 990-1003
13. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000; 101 (17): 2118-21
14. Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001; 104 (7): 779-82
15. Redfield MM, Jacobsen SJ, Burnett Jr JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202
16. Tsang TS, Barnes ME, Gersh BJ, et al. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002; 90 (12): 1284-9
17. Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. J Am Coll Cardiol 2003; 41 (11): 2010-7
18. Yamaguchi H, Yoshida J, Yamamoto K, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43 (1): 55-60
19. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-62
20. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiologic characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 2144-50
21. Chen HH, Lainchbury JG, Senni M, et al. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail 2002; 8 (5): 279-87
22. McDermott MM, Feinglass J, Sy J, et al. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. Am J Med 1995; 99 (6): 629-35
23. Labovitz AJ, Lewen MK, Kern M, et al. Evaluation of left ventricular systolic and diastolic dysfunction during transient myocardial ischemia produced by angioplasty. J Am Coll Cardiol 1987; 10 (4): 748-55
24. Mahmarian JJ, Pratt CM. Silent myocardial ischemia in patients with coronary artery disease: possible links with diastolic left ventricular dysfunction. Circulation 1990; 81 (2 Suppl.): III33-40
25. Pardaens K, Van Cleemput J, Vanhaecke J, et al. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart 1997; 78 (6): 564-8
26. Rich MW, McSherry F, Williford WO, et al. Effect of age on mortality, hospital izations and response to digoxin in patients with heart failure: the DIG Study. J Am Coll Cardiol 2001; 38 (3): 806-13
27. Tarantini L, Faggiano P, Senni M, et al. Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists: data from the Italian Network on Congestive Heart Failure. Ital Heart J 2002; 3 (11): 656-64
28. McDermott MM, Feinglass J, Lee PI, et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 1997; 134 (4): 728-36
29. Judge KW, Pawitan Y, Caldwell J, et al. Congestive heart failure symptoms in patients with preserved left ventricular systolic function: analysis of the CASS registry. J Am Coll Cardiol 1991; 18 (2): 377-82
30. Philbin EF, Rocco TA, Lindenmuth NW, et al. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000; 109 (8): 605-13
31. Pernenkil R, Vinson JM, Shah AS, et al. Course and prognosis in patients ≥70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol 1997; 79 (2): 216-9
32. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34 (1): 29-34
33. O'Connor CM, Gattis WA, Shaw L, et al. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol 2000; 86 (8): 863-7
34. Raev DC. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care 1994; 17 (7): 633-9
35. Seneviratne BI. Diabetic cardiomyopathy: the preclinical phase. Br Med J 1977; 1 (6074): 1444-6
36. Zabalgoitia M, Ismaeil MF, Anderson L, et al. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001; 87 (3): 320-3
37. Liu JE, Palmieri V, Roman MJ, et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001; 37 (7): 1943-9
38. Uusitupa M, Siitonen O, Aro A, et al. Effect of correction of hyperglycemia on left ventricular function in non-insulin-dependent [type 2] diabetics. Acta Med Scand 1983; 213 (5): 363-8
39. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103 (22): 2668-73
40. Poirier P, Bogaty P, Garneau C, et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001; 24 (1): 5-10
41. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: I. diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105 (11): 1387-93
42. Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relation. Circ Res 1989; 64 (5): 827-52
43. Huang B, Wang S, Qin D, et al. Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G[i] protein, phosphodiesterase, and phosphatases. Circ Res 1999; 85 (9): 848-55
44. Brittsan AG, Kranias EG. Phospholamban and cardiac contractile function. J Mol Cell Cardiol 2000; 32 (12): 2131-9
45. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997; 96 (11): 4065-82
46. Hardin NJ. The myocardial and vascular pathology of diabetic cardiomyopathy. Coron Artery Dis 1996; 7 (2): 99-108
47. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part II: causal mechanisms and treatment. Circulation 2002; 105 (12): 1503-8
48. Cain BS, Meldrum DR, Joo KS, et al. Human SERCA2a levels correlate inversely with age in senescent human myocardium. J Am Coll Cardiol 1998; 32 (2): 458-67
49. Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003; 42 (2): 328-35
50. Penpargkul S, Fein F, Sonnenblick EH, et al. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol 1981; 13 (3): 303-9
51. Teshima Y, Takahashi N, Saikawa T, et al. Diminished expression of sarcoplasmic reticulum Ca2+ ATPase and ryanodine sensitive Ca2+ channel mRNA in streptozotocin-induced diabetic rat heart. J Mol Cell Cardiol 2000; 32 (7): 655-64
52. Belke DD, Dillmann WH. Altered cardiac calcium handling in diabetes. Curr Hypertens Rep 2004; 6 (6): 424-9
53. Jalil JE, Doering CW, Janicki JS, et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989; 64 (6): 1041-50
54. Weber KT, Janicki JS, Pick R, et al. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 1990; 65 (14): 1G-7G
55. Kato S, Spinale FG, Tanaka R, et al. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol 1995; 269 (3 Pt 2): H863-8
56. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002; 27 (2): 92-8
57. Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977; 60 (4): 885-99
58. Nunoda S, Genda A, Sugihara N, et al. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1985; 1 (1): 43-7
59. Das AK, Das JP, Chandrasekar S. Specific heart muscle disease in diabetes mellitus: a functional structural correlation. Int J Cardiol 1987; 17 (3): 299-302
60. Genda A, Mizuno S, Nunoda S, et al. Clinical studies on diabetic myocardial disease using exercise testing with myocardial scintigraphy and endomyocardial biopsy. Clin Cardiol 1986; 9 (8): 375-82
61. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990; 82 (3): 848-55
62. Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 23 (4758): 1629-32
63. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996; 93 (10): 1905-12
64. Regan TJ, Wu CF, Yeh CK, et al. Myocardial composition and function in diabetes: the effects of chronic insulin use. Circ Res 1981; 49: 1268-77
65. Shimizu M, Umeda K, Sugihara N, et al. Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol 1993; 46 (1): 32-6
66. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101 (8): 899-907
67. Spiro MJ, Crowley TJ. Increased rat myocardial type VI collagen in diabetes mellitus and hypertension. Diabetologia 1993; 36 (2): 93-8
68. Mott JD, Khalifah RG, Nagase H, et al. Nonenzymatic glycation of type IV collagen and matrix metalloprotease susceptibility. Kidney Int 1997; 52 (5): 1302-12
69. Vishwanath V, Frank KE, Elmets CA, et al. Glycation of skin collagen in type I diabetes mellitus: correlation with long-term complications. Diabetes 1986; 35 (8): 916-21
70. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med 1992; 117: 502-10
71. Gaasch WH. Congestive heart failure in patients with normal left ventricular systolic function: a manifestation of diastolic dysfunction. Herz 1991; 16: 22-32
72. Ledet T. Histological and histochemical changes in the coronary arteries of old diabetic patients. Diabetologia 1968; 4 (5): 268-72
73. Fischer VW, Barner HB, Leskiw ML. Capillary basal laminar thichness in diabetic human myocardium. Diabetes 1979; 28 (8): 713-9
74. Factor SM, Okun EM, Minase T. Capillary microaneurysms in the human diabetic heart. N Engl J Med 1980; 302 (7): 384-8
75. Zoneraich S, Silverman G, Zoneraich O. Primary myocardial disease, diabetes mellitus, and small vessel disease. Am Heart J 1980; 100 (5): 754-5
76. Pitzalis MV, Iacoviello M, Massari F, et al. Influence of gender and family history of hypertension on autonomic control of heart rate, diastolic function and brain natriuretic peptide. J Hypertens 2001; 19 (1): 143-8
77. Friedrich SP, Lorell BH, Rousseau MF, et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994; 90 (6): 2761-71
78. Schunkert H, Jackson B, Tang SS, et al. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993; 87 (4): 1328-39
79. Flesch M, Schiffer F, Zolk O, et al. Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca (2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertens 1997; 15 (9): 1001-9
80. Yamamoto K, Masuyama T, Sakata Y, et al. Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system. Cardiovasc Res 2000; 46 (3): 421-32
81. Lopez B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104 (3): 286-91
82. Varo N, Iraburu MJ, Varela M, et al. Chronic AT (1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35 (6): 1197-202
83. Fiordaliso F, Li B, Latini R, et al. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent. Lab Invest 2000; 80 (4): 513-27
84. Hong SJ, Park CG, Seo HS, et al. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 2004; 13 (4): 236-42
85. Liao Y, Takashima S, Maeda N, et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005; 67 (4): 705-13
86. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005; 85 (3): 1093-129
87. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes. Part II: potential mechanisms. Circulation 2002; 105 (15): 1861-70
88. Iozzo P, Chareonthaitawee P, Dutka D, et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002; 51 (10): 3020-4
89. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25 (4): 543-67
90. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 1998; 180 (1-2): 53-7
91. Depre C, Young ME, Ying J, et al. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 2000; 32 (6): 985-96
92. Golfman L, Dixon IM, Takeda N, et al. Differential changes in cardiac myofibrillar and sarcoplasmic reticular gene expression in alloxan-induced diabetes. Mol Cell Biochem 1999; 200 (1-2): 15-25
93. Rich MW, McSherry F, Williford WO, et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001; 38 (3): 806-13
94. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362 (9386): 777-81
95. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation2005; 112 (12): e154-235. Epub 2005 Sep 13
96. Kawasaki D, Kosugi K, Waki H, et al. Long-term angiotensin II receptor blockade improves left ventricular diastolic filling in diabetic patients trough modulation of collagen type 1 turnover and diastolic property [abstract]. Circulation 2005; 112 (17 Suppl.): II-505
97. Hayashi T, Sohmiya K, Ukimura A, et al. Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart. Heart 2003; 89 (10): 1236-42
98. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101 (22): 2612-7
99. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45 (5): 712-9
100. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15 (1): 79-87
101. Pitt B, Remme W, Zannad F, et al. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators: eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348 (14): 1309-21. Epub 2003 Mar 31
102. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110 (5): 558-65
103. Roongsritong C, Sutthiwan P, Bradley J, et al. Spironolactone improves diastolic function in the elderly. Clin Cardiol 2005; 28 (10): 484-7
104. Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005 Nov 8; 112 (19): 2940-5
105. CIBIS-II investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9-13
106. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353 (9169): 2001-7
107. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334 (21): 1349-55
108. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344 (22): 1651-8
109. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339 (8): 489-97
110. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317 (7160): 703-13
111. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998; 41 (1 Suppl. 1): 39-52
112. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334 (6): 374-81
113. Bakris GL, Fonseca V, Katholi RE, et al. GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292 (18): 2227-36
114. Mohacsi P, Fowler MB, Krum H, et al. Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study [abstract]. Circulation 2001; 104 Suppl. II: II-754
115. Bristow MR. Effect of carvedilol on LV function and mortality in diabetic vs nondiabetic patients with ischemic or nonischemic dilated cardiomyopathy [abstract]. Circulation 1996; 84: I-664
116. Wedel H, Demets D, Deedwania P, et al. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 2001; 142 (3): 502-11
117. Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001 Aug; 3 (4): 469-79
118. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13
119. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26 (3): 215-25
120. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108 (8): 1105-7
121. American Society of Health System Pharmacists. AHFS drug information. Bethesda (MD): American Society of Health-System Pharmacists, 2004
122. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28 (10): 2345-51
123. Nichols GA, Koro CE, Gullion CM, et al. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005; 21 (1): 51-7
124. Russell III RR, Li J, Coven DL, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114 (4): 495-503
125. Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 2004; 27 (7): 1791-3
126. Inzucchi SE. Metformin and heart failure: innocent until proven guilty. Diabetes Care 2005; 28 (10): 2585-7
127. McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. CMAJ 2005; 173 (5): 502-4
128. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones [published erratum appears in Ann Intern Med 2001; 135 (4): 307]. Ann Intern Med 2001 Jan 2; 134 (1): 61-71
129. Dormandy JA, Charbonnel B, Eckland D, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366 (9493): 1279-89
130. Nesto RW, Bell D, Bonow RO, et al. American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003; 108 (23): 2941-8
131. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111 (5): 583-90
132. Tsuji T, Mizushige K, Noma T, et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 2001; 38 (6): 868-74
133. Hirayama H, Sugano M, Abe N, et al. Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients. Int J Cardiol 2001; 77 (1): 75-9
134. Horio T, Suzuki M, Suzuki K, et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005; 18 (7): 949-57
135. Srivastava PM, Calafiore P, MacIsaac RJ, et al. Thiazolidinediones and congestive heart failure: exacerbation or new onset of left ventricular dysfunction? Diabet Med 2004; 21 (8): 945-50
136. Quast U, Stephan D, Bieger S, et al. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004; 53 Suppl. 3: S156-64
137. Bienengraeber M, Olson TM, Selivanov VA, et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet 2004; 36 (4): 382-7. Epub 2004 Mar 21
138. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results. Diabetes 1970; (19 Suppl.): 789-830
139. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53
140. Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf 2000; 22 (4): 313-20
141. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290 (4): 486-94
142. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005; 46 (6): 1019-26